Dr. Park on Potential Alternate CAR T-Cell Targets in B-Cell Malignancies

Video

Jae H.Park, MD, discusses potential alternate CAR T-cell targets in B-cell malignancies.

Jae H. Park, MD, attending physician, Leukemia Service and Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses potential alternate CAR T-cell targets in B-cell malignancies.

Though significant response rates have been demonstrated with CD19-targeting CAR T-cells, investigation into other possible B-cell antigen targets are ongoing, says Park. CD22 is of particular interest, though responses do not appear as durable as those seen with CD19-targeting antigens.

Additionally, dual-targeting CAR T-cell therapy may increase response rates in this field. At the 2019 ASH Annual Meeting, an update from a phase I dose-climbing study (ChiCTR1800018143) showed objective response rates of over 90% was shown with CAR T-cells targeting both CD38 and BCMA in patients with extramedullary multiple myeloma.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.